Vir plots IPO as more programs near clinic

Although more than half of the $630.7 million in equity funding that Vir Biotechnology has raised remains unspent, the immunology and infectious disease company -- led by former Biogen and Exelixis CEO George Scangos -- is now aiming to raise up to $100 million in an IPO on NASDAQ.

Vir Biotechnology Inc. (San Francisco, Calif.) filed late Wednesday for the listing, with Goldman Sachs, J.P. Morgan, Cowen and Barclays as underwriters...